NASDAQ: ERAS

Erasca Inc Stock Forecast, Predictions & Price Target

The consensus among 5 Wall Street analysts covering (NASDAQ: ERAS) stock is to Buy ERAS stock.

Out of 5 analysts, 2 (40%) are recommending ERAS as a Strong Buy, 2 (40%) are recommending ERAS as a Buy, 1 (20%) are recommending ERAS as a Hold, 0 (0%) are recommending ERAS as a Sell, and 0 (0%) are recommending ERAS as a Strong Sell.

If you're new to stock investing, here's how to buy Erasca stock.

(NASDAQ: ERAS) Erasca's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Erasca's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ERAS's revenue for 2026 to be $2,743,559,256, with the lowest ERAS revenue forecast at $2,743,559,256, and the highest ERAS revenue forecast at $2,743,559,256. On average, 2 Wall Street analysts forecast ERAS's revenue for 2027 to be $3,787,354,025, with the lowest ERAS revenue forecast at $2,120,918,254, and the highest ERAS revenue forecast at $5,453,789,796.

In 2028, ERAS is forecast to generate $19,174,615,958 in revenue, with the lowest revenue forecast at $16,967,346,032 and the highest revenue forecast at $21,381,885,884.

According to 5 Wall Street analysts that have issued a 1 year ERAS price target, the average ERAS price target is $7.20, with the highest ERAS stock price forecast at $8.00 and the lowest ERAS stock price forecast at $6.00.

On average, Wall Street analysts predict that Erasca's share price could reach $7.20 by Apr 2, 2025. The average Erasca stock price prediction forecasts a potential upside of 302.23% from the current ERAS share price of $1.79.

(NASDAQ: ERAS) forecast ROE is N/A, which is considered weak.